| Literature DB >> 35686143 |
Mebrahtu Tweldemedhin1, Saravanan Muthupandian1,2, Tsega Kahsay Gebremeskel1, Kibrti Mehari1, Getahun Kahsay Abay1, Teklay Gebrecherkos Teklu1, Ranjithkumar Dhandapani3, Ragul Paramasivam3, Tsehaye Asmelash1.
Abstract
Purpose: The emergence of antimicrobial resistance is a major global health challenge and becoming an urgent priority for policymakers. There is a paucity of scientific studies presenting the multidrug resistance pattern from one health perspective in Ethiopia. Therefore, a systematic review and meta-analysis aimed to determine the pooled prevalence of multidrug resistance in bacteria from human, animal, food, and environmental sources.Entities:
Keywords: Antimicrobial resistance; CI, Confidence interval; CoNS, Coagulase-negative Staphylococci; ES, Estimate; Ethiopia; MDR, Multidrug resistance; Multidrug resistance; One health; bacteria
Year: 2022 PMID: 35686143 PMCID: PMC9171526 DOI: 10.1016/j.onehlt.2022.100390
Source DB: PubMed Journal: One Health ISSN: 2352-7714
Fig. 1Prisma flow chart showing the selection process of articles on antimicrobial resistance in Ethiopia.
Description of included studies based on the study area: clustered into regions.
| Description | Number of studies | Percentage | |
|---|---|---|---|
| Study area | Addis Ababa area | 19 | 23.5 |
| Eastern Ethiopia | 5 | 6.5 | |
| Southern Ethiopia | 11 | 13.6 | |
| Oromia region | 13 | 16 | |
| Amhara region | 21 | 25.9 | |
| Tigray region | 12 | 14.8 | |
| Total | 81 | 100 | |
N: indicates the number of studies.
Description of human studies (n = 53).
| Disease condition (n) | Type of sample taken (n) |
|---|---|
| Multiple infections (14) | Multiple clinical samples (14) |
| Nasal/nasopharyngeal Colonization (11) | Nasal/nasopharyngeal swab (12) |
| Skin colonization (1) | Skin swab (1) |
| Intestinal infection/colonization (11) | Stool (14) |
| Sepsis (4), Enteric fever (2) | Blood (4) |
| Genital colonization/infection (6) | Viginal swab &rectal swab/urethral discharge/cervical swab (6) |
| UTI (5) | Urine (5) |
| Ocular infection (5) | Eye discharge or swab (5) |
| Ear infection (2) | Ear discharge (2) |
| Nosocomial infection (2) | Multiple clinical samples (2) |
N: indicates the number of studies.
Description of Animal, food, and environmental studies.
| Animal studies (8) | |
|---|---|
| Type of animal (n) | Type of sample taken (n) |
| Cattle (3) | Feces (1), Milk (1), Feces &surface swab (1) |
| Chicken (1) | Visceral organ samples (1) |
| Dog (1) | Rectal swab (1) |
| Goat (1) | Different clinical samples (1) |
| Cockroaches (2) | External and internal body samples (2) |
N: indicates the number of studies associated with that particular description.
The type of bacterial isolates considered for the meta-analysis.
| Type of bacteria | Number of studies from each source | Reference | |||
|---|---|---|---|---|---|
| Humans | Animals | Environment/Food | Total | ||
| 25 | 3 | 9 | 37 | [ | |
| 12 | 1 | 7 | 8 | [ | |
| 5 | – | – | 5 | [ | |
| 8 | – | – | 8 | [ | |
| 8 | – | – | 8 | [ | |
| 6 | – | – | 6 | [ | |
| 19 | 4 | 14 | 37 | [ | |
| 18 | 1 | 7 | 26 | [ | |
| 15 | 1 | 3 | 19 | [ | |
| 14 | 1 | 5 | 20 | [ | |
| 12 | 5 | 6 | 23 | [ | |
| 11 | 2 | – | 13 | [ | |
| 11 | 1 | 2 | 14 | [ | |
| 7 | 1 | 1 | 9 | [ | |
| 7 | – | 1 | 8 | [ | |
| 11 | – | 5 | 16 | [ | |
| 4 | – | – | 4 | [ | |
| 4 | – | – | 4 | [ | |
| 4 | – | – | 4 | [ | |
A summary of the pooled proportion of MDR for each gram-positive bacterium included in the meta-analysis, 2015–2020.
| Type of bacteria | Estimate (95%CI) for bacterial isolates from each source | Overall pooled proportion | Heterogeneity between groups | ||
|---|---|---|---|---|---|
| Humans | Animals | Environment/Food | |||
| 0.57 (0.44, 0.70) | 0.32(0.00, 0.97) | 0.49 (0.31, 0.68) | 0.53 (0.42, 0.64), I2 = 96.10% p = 0.000 | P = 0.677 | |
| 0.78(0.62–0.91) | – | 0.51(0.28–0.74) | 0.68 (0.53–0.82), I2 = 93.35% p = 0.00 | P = 0.062 | |
| 0.42(0.07–0.80) | – | – | I2 = 83.07% p = 0.00 | NA | |
| 0.51(0.15–0.89) | – | – | I2 = 92.83% p = 0.00 | NA | |
| 0.27(0.10–0.47) | – | – | I2 = 88.26% p = 0.01 | NA | |
| 0.65(0.41–0.85) | – | – | I2 = 88.69% p = 0.000 | NA | |
A summary of the pooled proportion of MDR for each gram-negative bacteria included in the meta-analysis, 2015–2020.
| Type of bacteria | Estimate (95%CI) for bacterial isolates from each source | Overall pooled proportion: ES (95%CI), I2 = % p = value | Heterogeneity between groups | ||
|---|---|---|---|---|---|
| Humans | Animals | Environment/Food | |||
| 0.81(0.70–090) | 0.72(0.57–0.86) | 0.53(0.35–0.70) | 0.70(0.61–0.78) | No, p = 0.035 | |
| 0.81(0.70–0.90) | – | 0.37(0.20–0.57) | 0.68(0.54–0.80) | Yes, P = 0.0000 | |
| 0.64(0.43–0.84) | – | 0.73(0.43–0.98) | 0.67(0.48–0.83) | No, P = 0.622 | |
| 0.73(0.54–0.90) | – | 0.69(0.32–0.97) | 0.71(0.54–0.87) | No, P = 0.849 | |
| 0.70(0.50–0.87) | 0.64(0.43–0.83) | 0.56(0.13–0.94) | 0.65(0.48–0.81) | No,0.068 | |
| 0.69(0.54–0.82) | – | – | I2 = 58.13% p = 0.01 | NA | |
| 0.54(0.34–0.75) | – | – | I2 = 57.50% p = 0.01 | NA | |
| 0.42(0.12–0.74) | – | – | I2 = 25.00% p = 0.24 | NA | |
| 0.86(0.46–1.00) | – | – | I2 = 77.69% p = 0.00 | NA | |
| 0.82(0.52–1.00) | – | 0.53(0.13–0.92) | 0.73 (0.48–0.93) | No, P = 0.312 | |
| 0.74(0.51–0.92) | – | – | I2 = 20.80% p = 0.29 | NA | |
| 0.44(0.00–0.95) | – | – | I2 = 81.29% p = 0.00 | NA | |
| 0.10(0.00–0.39) | – | – | I2 = 0.00% p = 0.99 | NA | |
NA: not applicable.
Fig. 2The Forest plot shows the pooled prevalence of multidrug-resistant (MDR) S. aureus in humans was 0.57(0.44, 0.70), 0.32(0.00, 0.97) in animal studies, and 0.49(0.31, 0.68) for isolates from the environment or food. There was no significant heterogeneity between the three sources; p = 0.677.
Fig. 3Forest plot of the pooled proportion of Coagulase-negative Staphylococci (CoNS) Multidrug-resistant (MDR) was 0.78(0.62–0.91) in human studies, 0.51(0.28–0.74) in environment or food with an overall estimated MDR of 68% and has no significant heterogeneity between the two sources.
Fig. 4The pooled prevalence of Multidrug-resistant (MDR) S. pyogens in humans was 0.42(0.07–0.80), I2 = 83.07%, and p = 0.
Fig. 5The pooled prevalence of multidrug- resistant (MDR) Streptococcus pneumoniae in humans was 0.27 (0.10–0.47), I2 = 88.26%, and p = 0.
Fig. 6The pooled prevalence of multidrug-resistant (MDR) S. agalactae in humans was 0.51(0.12–0.89), I2 = 92.83%, and p = 0.